000865149 001__ 865149
000865149 005__ 20210130002930.0
000865149 037__ $$aFZJ-2019-04699
000865149 1001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b0$$ufzj
000865149 1112_ $$a14th Meeting of the European Association of Neurooncology$$cLyon$$d2019-09-19 - 2019-09-22$$wFrankreich
000865149 245__ $$aSpatial discrepancies between FET PET and conventional MRI in patients with newly diagnosed glioblastoma
000865149 260__ $$c2019
000865149 3367_ $$033$$2EndNote$$aConference Paper
000865149 3367_ $$2DataCite$$aOther
000865149 3367_ $$2BibTeX$$aINPROCEEDINGS
000865149 3367_ $$2DRIVER$$aconferenceObject
000865149 3367_ $$2ORCID$$aLECTURE_SPEECH
000865149 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1568639176_13616$$xInvited
000865149 520__ $$aP14.32 SPATIAL DISCREPANCIES BETWEEN FET PET AND CONVENTIONAL MRI IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAP.  Lohmann1, P.  Stavrinou2, K. Lipke1, E. K. Bauer3, G. Ceccon3, J. Werner3, G. R. Fink1,3, N. J. Shah1,4, K. Langen1,5, N. Galldiks1,3; 1Institute of Neuroscience and Medicine (INM-3,-4), Research Center Juelich, Juelich, Germany, 2Department of Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, 3Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, 4Department of Neurology, University Hospital RWTH Aachen, Aachen, Germany, 5Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.BACKGROUND:  In  patients  with  glioblastoma,  the  tissue  showing  contrast  enhancement  (CE)  in  MRI  is  usually  the  target  for  resection  or  radiotherapy.  However,  the  solid  tumor  mass  typically  extends  beyond  the  area  of  CE.  Amino  acid  PET  can  detect  tumor  parts  that  show  no  CE.  We  systematically  investigated  tumor  volumes  delineated  by  amino  acid  PET  and  MRI  in  newly  diagnosed,  untreated  glioblastoma  patients.  MATERIAL  AND  METHODS:  Preoperatively,  50  patients  with  subse-quently   neuropathologically   confirmed   glioblastoma   underwent   O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET, fluid-attenuated inversion recovery (FLAIR),  and  CE  MRI.  Areas  of  CE  were  manually  delineated.  FET  PET  tumor volumes were segmented using a tumor-to-brain ratio ≥ 1.6. The per-centage  of  overlapping  volumes  (OV),  as  well  as  Dice  and  Jaccard  spatial  similarity coefficients (DSC; JSC), were calculated. FLAIR images were evalu-ated visually. RESULTS:  In 86% of patients (n = 43), the FET PET tumor volume was significantly larger than the volume of CE (21.5 ± 14.3 mL vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients (80%) showed both an increased uptake of FET and CE. In these 40 patients, the spatial similarity between FET and CE was low (mean DSC, 0.39 ± 0.21; mean JSC, 0.26 ± 0.16). Ten patients  (20%)  showed  no  CE,  and  one  of  these  patients  showed  no  FET  uptake. In 10% of patients (n = 5), increased FET uptake was present out-side  of  areas  of  FLAIR  hyperintensity.  CONCLUSION:   Our  results  show  that the metabolically active tumor volume delineated by FET PET is signifi-cantly larger than tumor volume delineated by CE. The data strongly suggest that  the  information  derived  from  FET  PET  should  be  integrated  into  the  management  of  newly  diagnosed  glioblastoma  patients.  FUNDING:  This  work was supported by the Wilhelm-Sander Stiftung, Germany
000865149 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000865149 7001_ $$0P:(DE-HGF)0$$aStavrinou, P.$$b1
000865149 7001_ $$0P:(DE-HGF)0$$aLipke, K.$$b2
000865149 7001_ $$0P:(DE-HGF)0$$aBauer, E. K.$$b3
000865149 7001_ $$0P:(DE-HGF)0$$aCeccon, G.$$b4
000865149 7001_ $$0P:(DE-HGF)0$$aWerner, J.$$b5
000865149 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b6$$ufzj
000865149 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b7$$ufzj
000865149 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b8$$ufzj
000865149 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b9$$ufzj
000865149 909CO $$ooai:juser.fz-juelich.de:865149$$pVDB
000865149 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b0$$kFZJ
000865149 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b6$$kFZJ
000865149 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b7$$kFZJ
000865149 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000865149 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b9$$kFZJ
000865149 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000865149 9141_ $$y2019
000865149 920__ $$lyes
000865149 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000865149 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000865149 980__ $$aconf
000865149 980__ $$aVDB
000865149 980__ $$aI:(DE-Juel1)INM-3-20090406
000865149 980__ $$aI:(DE-Juel1)INM-4-20090406
000865149 980__ $$aUNRESTRICTED